top of page

Research Networks

The CIB works with our collaborators to develop or manage disease consortia and networks.  Below are just a few of the disease networks we are currently involved in:


Amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig's disease, is a rapidly progressive, invariably fatal neurological disease that attacks the nerve cells (neurons) responsible for controlling voluntary muscles (muscle action we are able to control, such as those in the arms, legs, and face). The disease belongs to a group of disorders known as motor neuron diseases, which are characterized by the gradual degeneration and death of motor neurons. (source)

  • ALS-FTD Longitudinal Outcomes Study

  • Answer ALS: Individualized Initiative for ALS Discovery

  • BIO3

  • C9orf72

  • CABB


  • GTAC

  • Iron Horse

  • Lunasin ALS Reversals

  • Microbiome

  • Natural History of ALS

  • Next Generation Sequencing in ALS

  • Platform Trial

  • Target ALS Multicenter Human Postmortem Tissue Core

  • TRACK-ALS-001

  • UMN Registry

  • Vitality ALS


Leukodystrophy refers to progressive degeneration of the white matter of the brain due to imperfect growth or development of the myelin sheath, the fatty covering that acts as an insulator around nerve fiber. Myelin, which lends its color to the white matter of the brain, is a complex substance made up of at least ten different chemicals. The leukodystrophies are a group of disorders that are caused by genetic defects in how myelin produces or metabolizes these chemicals. Each of the leukodystrophies is the result of a defect in the gene that controls one (and only one) of the chemicals. The most common symptom of a leukodystrophy disease is a gradual decline in an infant or child who previously appeared well. Progressive loss may appear in body tone, movements, gait, speech, ability to eat, vision, hearing, and behavior. There is often a slowdown in mental and physical development. Symptoms vary according to the specific type of leukodystrophy, and may be difficult to recognize in the early stages of the disease. (source)

  • ALD Natural History

  • Canavan

  • GLIA Network

  • Late Onset Tay-Sachs

Other Neurological Diseases
  • Alzheimer’s

  • Olfactory Deficits in Neurological Disease

  • Frontotemporal Dementia (FTD)

  • Vascular Cognitive Impairment and Dementia (VCID)

  • X-Linked Dystonia Parkinsonism

bottom of page